Alkermes, Inc.

This study tests whether a combination drug called OLZ/SAM (olanzapine plus samidorphan) causes less weight gain than olanzapine alone in teenagers with schizophrenia or bipolar I disorder. About 220 teens aged 10-17 will take either the combo or olanzapine for 52 weeks. The main…

This study tests a new drug called ALKS 2680 to see if it can safely reduce daytime sleepiness in people with idiopathic hypersomnia, a condition causing excessive sleepiness without clear cause. About 126 participants will receive either the drug or a placebo daily for 8 weeks. …

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce severe daytime sleepiness and sudden muscle weakness (cataplexy) in adults with narcolepsy type 1. About 150 participants will receive either the drug or a placebo for 12 weeks. The study measures improve…

This study tests a new tablet called ALKS 2680 to see if it can reduce daytime sleepiness in adults with narcolepsy type 2. About 176 participants will receive either the study drug or a placebo for 12 weeks. The main goal is to measure how well they can stay awake using a standa…

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tes…

This study is testing the long-term safety and how well ALKS 2680 works over time in people with narcolepsy type 1, type 2, or idiopathic hypersomnia. Participants take a once-daily tablet at different doses. The goal is to see if the drug remains safe and effective for staying a…